Contents
Special Issue Topic

Novel Strategies and Targets for Immunotherapy of Cancer

Guest Editor

Prof. Seiji Okada E-Mail

Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Research Keywords: Targeting therapy; cancer immunotherapy; precision medicine; animal model; Patient-derived xenograft (PDX)

About the Special lssue

Immunotherapy is a type of cancer treatment that helps the patients’ immune system to fight with cancer by boosting the power of immune cells. Immunotherapy used to be the way to nonspecifically activate immune system by cytokines or immune stimulants such as BCG, and it was just an adjunctive therapy of surgery, chemotherapy and radiotherapy. Recently, immunotherapy is becoming the main actor of cancer therapy by developing various therapeutic approaches and therapies such as monoclonal antibodies, immune check point inhibitors, T-cell transfer therapy such as CAR-T therapy, etc. Immune system modulators such as interferons are also clinically in use and effective in some sort of cancers. These immunotherapies still have ample scope for improvement. The aim of this special issue is to discuss the latest progress and future direction of cancer immunotherapy. We accept original research articles, critical review papers and commentaries that provide novel approaches and highlight the promising targets for cancer immunotherapies.

Keywords: Immunotherapy; CAR-T; therapeutic monoclonal antibodies; immunomodulators; treatment vaccines; immune checkpoint inhibitors

Published Articles

Open Access Review
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
Ken Akao ... Kazuyoshi Imaizumi
Published: July 19, 2024 Explor Target Antitumor Ther. 2024;5:826–840
2211 29 1
Open Access Review
Immunopeptidomics in the cancer immunotherapy era
Sutatip Pongcharoen ... Supachai Topanurak
Published: July 17, 2024 Explor Target Antitumor Ther. 2024;5:801–817
3478 82 1
Open Access Review
Promising immunotherapeutic approaches for primary effusion lymphoma
Jutatip Panaampon, Seiji Okada
Published: June 26, 2024 Explor Target Antitumor Ther. 2024;5:699–713
2037 27 5
Open Access Review
Tri-specific killer engager: unleashing multi-synergic power against cancer
Peeranut Winidmanokul ... Seiji Okada
Published: April 25, 2024 Explor Target Antitumor Ther. 2024;5:432–448
4174 88 2
Open Access Review
Magnetite nanoparticles: an emerging adjunctive tool for the improvement of cancer immunotherapy
Phoomipat Jungcharoen ... Charupong Saengboonmee
Published: April 23, 2024 Explor Target Antitumor Ther. 2024;5:316–331
2323 34 5
Open Access Review
Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment
Eric Jou ... Fizza Nasim
Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:187–207
4714 61 10
Open Access Review
Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma
Hiroki Goto ... Seiji Okada
Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:208–224
3192 101 9
Open Access Case Report
A case of immunotherapy-induced thyroiditis
George Pears ... Joseph Sacco
Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:225–231
3612 31 0
Open Access Review
CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia
Kamonporn Kotemul ... Nuchjira Takheaw
Published: February 19, 2024 Explor Target Antitumor Ther. 2024;5:96–107
2653 36 6
Open Access Review
Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes
Chaoqun Li ... Jieer Ying
Published: December 28, 2023 Explor Target Antitumor Ther 2023;4:1310–1327
2113 16 1
Open Access Original Article
Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy
Witida Laopajon ... Watchara Kasinrerk
Published: December 06, 2023 Explor Target Antitumor Ther. 2023;4:1145–1156
2159 28 0
Open Access Commentary
A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?
Dimitrios Bouzianas, Stella Bouziana
Published: October 31, 2023 Explor Target Antitumor Ther. 2023;4:1128–1135
2121 22 2